keyword
MENU ▼
Read by QxMD icon Read
search

Toxic epidermal

keyword
https://www.readbyqxmd.com/read/28730261/post-medication-stevens-johnson-syndrome-in-a-girl-hospitalized-for-a-norovirus-and-rotavirus-infection
#1
Simona Dumitra, LuminiŢa Pilat, Alina Iftode, Ozana Nicoleta Bălan, Carmen Ramona StănculeŢ, Elena Claudia Covaci, Alexandru Fica Mircea Onel, Carmen Nicoleta Crişan
Stevens-Johnson syndrome (SJS) is a cutaneous mucosal disorder characterized by extended necrosis and detachment of the epidermis affecting <10% of the body surface, caused by drugs or infections. The authors report a case of a girl with Depakine resistant epilepsy, who develops a SJS in the third week of introducing lamotrigine. The girl also presents an acute diarrheal disease with double viral etiology - rotavirus and norovirus. The clinical image comprises polymorphic erythematous maculopapular exanthema with vesicular and bullous elements, with ulcerations and desquamations at the level of the eyelids, mouth, anogenital area and tegument denuding at the level of the abdomen and limbs...
2017: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
https://www.readbyqxmd.com/read/28727517/comparative-toxicity-and-effectiveness-of-trastuzumab-based-chemotherapy-regimens-in-older-women-with-early-stage-breast-cancer
#2
Katherine E Reeder-Hayes, Anne Marie Meyer, Sharon Peacock Hinton, Ke Meng, Lisa A Carey, Stacie B Dusetzina
Purpose The combination of chemotherapy and trastuzumab is the standard of care for adjuvant treatment of human epidermal growth factor receptor 2-positive breast cancer. Two regimens have been widely adopted in the United States: doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab (ACTH) and docetaxel, carboplatin, and trastuzumab (TCH). No head-to-head comparison of these regimens has been conducted in a clinical trial, and existing trial data have limited generalizability to older patients. Methods We used SEER-Medicare data from 2005 to 2013 to compare outcomes of ACTH versus TCH among patients age older than 65 years...
July 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28724908/design-and-discovery-of-novel-monastrol-1-3-5-triazines-as-potent-anti-breast-cancer-agent-via-attenuating-epidermal-growth-factor-receptor-tyrosine-kinase
#3
Jitendra Kumar Srivastava, Girinath G Pillai, Hans Raj Bhat, Amita Verma, Udaya Pratap Singh
A novel series of hybrid analogues of monastrol-1,3,5-triazine were designed and developed via one-pot synthesis using Bi(NO3)3 as a catalyst. Entire compounds were evaluated for their anticancer activity against HeLa (cervical cancer), MCF-7 (breast cancer), HL-60 (Human promyelocytic leukemia), HepG2 (Hepatocellular carcinoma) and MCF 12A (normal epithelial breast cell line) using MTT assay, where they showed highest inhibitory activity against MCF-7. The molecules were also found to be non-toxic to MCF 12A cells...
July 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28724844/a-review-of-the-active-treatments-for-toxic-epidermal-necrolysis
#4
Yuri Kinoshita, Hidehisa Saeki
Toxic epidermal necrolysis (TEN) is a severe adverse drug reaction associated with the separation of skin and mucous membranes at the dermal-epidermal junction. Although it is rare, many treatments have been trialed because of its high mortality rate. Active interventions performed to date include the use of systemic corticosteroids, intravenous immunoglobulins (IVIg), cyclosporine, plasmapheresis, anti-tumor necrosis factor drugs and N-acetylcysteine, but none has been established as the most effective therapy...
2017: Journal of Nippon Medical School, Nippon Ika Daigaku Zasshi
https://www.readbyqxmd.com/read/28724573/a-single-dose-of-peripherally-infused-egfrviii-directed-car-t-cells-mediates-antigen-loss-and-induces-adaptive-resistance-in-patients-with-recurrent-glioblastoma
#5
Donald M O'Rourke, MacLean P Nasrallah, Arati Desai, Jan J Melenhorst, Keith Mansfield, Jennifer J D Morrissette, Maria Martinez-Lage, Steven Brem, Eileen Maloney, Angela Shen, Randi Isaacs, Suyash Mohan, Gabriela Plesa, Simon F Lacey, Jean-Marc Navenot, Zhaohui Zheng, Bruce L Levine, Hideho Okada, Carl H June, Jennifer L Brogdon, Marcela V Maus
We conducted a first-in-human study of intravenous delivery of a single dose of autologous T cells redirected to the epidermal growth factor receptor variant III (EGFRvIII) mutation by a chimeric antigen receptor (CAR). We report our findings on the first 10 recurrent glioblastoma (GBM) patients treated. We found that manufacturing and infusion of CAR-modified T cell (CART)-EGFRvIII cells are feasible and safe, without evidence of off-tumor toxicity or cytokine release syndrome. One patient has had residual stable disease for over 18 months of follow-up...
July 19, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28721106/adverse-reactions-in-leprosy-patients-who-underwent-dapsone-multidrug-therapy-a-retrospective-study
#6
Sanjeev Guragain, Namrata Upadhayay, Bishwa Mohan Bhattarai
OBJECTIVE: To investigate the occurrence and clinical characteristics of dapsone-related adverse drug reactions (ADRs) among leprosy patients who underwent multidrug therapy (MDT) from 2010 to 2013 in the western region of Nepal. METHODS: A retrospective review was carried out in the rehabilitation center. Data were collected from the record files of the hospital. RESULTS: From 2010 to 2013, there were 18 patients reported to have dapsone ADRs, with an occurrence rate of 0...
2017: Clinical Pharmacology: Advances and Applications
https://www.readbyqxmd.com/read/28721096/comparison-of-gefitinib-as-first-and-second-line-therapy-for-advanced-lung-adenocarcinoma-patients-with-positive-exon-21-or-19-del-epidermal-growth-factor-receptor-mutation
#7
Nishant Patel, Pingping Wu, Haijun Zhang
OBJECTIVES: Gefitinib, a tyrosine kinase inhibitor (TKI) targeting epidermal growth factor receptor (EGFR), shows excellent clinical benefit in treating advanced non-small-cell lung cancer (NSCLC). The aim of this study was to compare the efficacy and toxicity of gefitinib as first-line therapy and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 (L858R) or exon 19 deletion of EGFR mutation. METHODS: We retrospectively analyzed the clinical data of 60 EGFR-mutated advanced lung adenocarcinoma patients from July 2011 to November 2015 who have received oral gefitinib 250 mg once daily...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28712098/precision-medicine-in-metastatic-colorectal-cancer-relevant-carcinogenic-pathways-and-targets-part-1-biologic-therapies-targeting-the-epidermal-growth-factor-receptor-and-vascular-endothelial-growth-factor
#8
REVIEW
Benjamin A Weinberg, Marion L Hartley, Mohamed E Salem
The survival of patients with metastatic colorectal cancer has improved dramatically in recent years, with overall survival exceeding 3 years in large randomized clinical trials. There are now several treatment options for patients with metastatic colorectal cancer. In addition to chemotherapy backbones utilizing fluoropyrimidine, oxaliplatin, and irinotecan combinations, biologic agents that target specific oncogenic pathways have contributed to the improved survival observed in this patient population. This class of medications includes epidermal growth factor receptor (EGFR)-targeted drugs (cetuximab and panitumumab) and vascular endothelial growth factor (VEGF)-targeted therapies (bevacizumab, ramucirumab, ziv-aflibercept, and regorafenib)...
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28711984/clarithromycin-co-administration-does-not-increase-irinotecan-cpt-11-toxicity-in-colorectal-cancer-patients
#9
Katsuya Makihara, Sayaka Nakamura, Kazuyo Miyagi, Hiroyuki Ueno, Izumi Nakata
PURPOSE: Irinotecan (CPT-11) is used to treat advanced colorectal cancer. The drug is activated by carboxylesterases and rendered inactive by CYP3A4. Recently, the efficacy of combining CPT-11 and anti-epidermal growth factor receptor (EGFR) agents was confirmed in patients with KRAS wild-type metastatic colorectal cancer. Clarithromycin (CAM) is a strong CYP3A inhibitor often used to prevent rash associated with anti-EGFR therapy. The objective of this study was to evaluate the risk of increased neutropenia and diarrhea in combining CPT-11 and CAM...
July 15, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28710842/severe-sequelae-of-erythema-multiforme-three-cases
#10
A Viarnaud, S Ingen-Housz-Oro, M Marque, L Valeyrie-Allanore, N Ortonne, J Gueudry, S Grootenboer-Mignot, M Muraine, E Bequignon, C Gagnière, F Schlemmer, P Wolkenstein, O Chosidow
Erythema multiforme (EM) is a skin condition for which main causes are infectious factors (Herpes simplex virus, Mycoplasma pneumoniae). Anti-plakin auto-antibodies are found in some patients (1) . EM must be distinguished from Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which are drug-induced in most cases (2-5) . This article is protected by copyright. All rights reserved.
July 14, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28710747/phase-i-study-of-chimeric-antigen-receptor-modified-t-cells-in-treating-her2-positive-advanced-biliary-tract-cancers-and-pancreatic-cancers
#11
Kaichao Feng, Yang Liu, Yelei Guo, Jingdan Qiu, Zhiqiang Wu, Hanren Dai, Qingming Yang, Yao Wang, Weidong Han
This phase I clinical trial (NCT01935843) is to evaluate the safety, feasibility, and activity of chimeric antigen receptor-engineered T cell (CART) immunotherapy targeting human epidermal growth factor receptor 2 (HER2) in patients with advanced biliary tract cancers (BTCs) and pancreatic cancers (PCs). Eligible patients with HER2-positive (>50%) BTCs and PCs were enrolled in the trial. Well cultured CART-HER2 cells were infused following the conditioning treatment composed of nab-paclitaxel (100-200 mg/m(2)) and cyclophosphamide (15-35 mg/kg)...
July 14, 2017: Protein & Cell
https://www.readbyqxmd.com/read/28709416/warfarin-induced-toxic-epidermal-necrolysis-in-combination-therapy-of-henoch-sch%C3%A3-nlein-purpura-nephritis-a-case-report
#12
Katsuaki Kasahara, Yoshimitsu Gotoh, Yoshiyuki Kuroyanagi, China Nagano
BACKGROUND: Toxic epidermal necrolysis (TEN) is a rare life-threatening condition almost exclusively attributed to drugs. The main etiologic factors for TEN are sulphonamides, anticonvulsants, and antibiotics; however, there are no published reports of warfarin causing TEN. CASE PRESENTATION: We present the case of a 3-year-old patient who developed TEN while receiving treatment for Henoch-Schönlein purpura nephritis (HSPN). With multiple-drug therapy comprising prednisolone, mizoribine, dipyridamole, and warfarin, it is difficult to detect which drug is the causative agent...
July 14, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28707485/common-and-uncommon-adverse-cutaneous-reactions-to-erlotinib-a-study-of-20-chinese-patients-with-cancer
#13
Huiling Zhu, Zhe Zhu, Weining Huang, Xiping Cheng, Jiaxi He, Chunping Xiong, Jiande Han
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is used for treating non-small cell lung cancers. It is frequently known to cause skin toxicities. Systemic toxicities and anaphylactic cutaneous reactions have been rarely mentioned. Adverse cutaneous reactions were reported in 20 patients, including 6 cases of anaphylactic dermatitis, 12 cases of acneiform rash, 9 cases of xerosis, 5 cases of nail changes, and 4 cases of hair changes. One case of anaphylactic dermatitis manifested as erythema with swelling on the face and neck, and others as erosive and scaly erythema on the fold of skin, or red macules, papules, plaques, and pigmentation on the whole body...
July 14, 2017: Cutaneous and Ocular Toxicology
https://www.readbyqxmd.com/read/28701571/neoadjuvant-therapy-with-weekly-nanoparticle-albumin-bound-paclitaxel-for-luminal-early-breast-cancer-patients-results-from-the-nabrax-study-geicam-2011-02-a-multicenter-non-randomized-phase-ii-trial-with-a-companion-biomarker-analysis
#14
Miguel Martín, José I Chacón, Antonio Antón, Arrate Plazaola, Elena García-Martínez, Miguel A Seguí, Pedro Sánchez-Rovira, José Palacios, Lourdes Calvo, Carmen Esteban, Enrique Espinosa, Agusti Barnadas, Norberto Batista, Angel Guerrero, Montserrat Muñoz, Estefania Romio, César Rodríguez-Martín, Rosalía Caballero, María I Casas, Federico Rojo, Eva Carrasco, Silvia Antolín
BACKGROUND: Nanoparticle albumin-bound paclitaxel (nab-Paclitaxel) is an alternative to standard taxanes for breast cancer (BC) treatment. We evaluated nab-Paclitaxel efficacy as neoadjuvant treatment for early estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) disease. MATERIALS AND METHODS: Women with ER+, HER2-, stage II-III BC were treated preoperatively with four cycles of weekly nab-Paclitaxel (150 mg/m(2)), 3 weeks on and 1 week off...
July 12, 2017: Oncologist
https://www.readbyqxmd.com/read/28695168/living-with-the-effects-of-cutaneous-toxicities-induced-by-treatment
#15
REVIEW
Andreas Charalambous
The introduction of targeted therapies in cancer treatment was accompanied with promising results including tumor control and patients survival benefits. However, these drugs just like their predecessors were associated with systemic side effects, including frequent and various cutaneous effects. Targeted therapies such as epidermal growth factor receptor, vascular endothelial growth factor receptor, kit, platelet-derived growth factor receptor, and BCR-ABL inhibitors as well as mammalian target of rapamycin inhibitors can induce cutaneous toxicities of varying severity...
July 2017: Asia-Pacific Journal of Oncology Nursing
https://www.readbyqxmd.com/read/28689274/impact-of-glutathione-transferases-genes-polymorphisms-in-nevirapine-adverse-reactions-a-possible-role-for-gstm1-in-sjs-ten-susceptibility
#16
Cinzia Ciccacci, Andrea Latini, Cristina Politi, Sandro Mancinelli, Maria C Marazzi, Giuseppe Novelli, Leonardo Palombi, Paola Borgiani
PURPOSE: Nevirapine (NVP) is used in developing countries as first-line treatment of HIV infection. Unfortunately, its use is associated with common serious adverse drug reactions, such as liver toxicity and the most severe and rare Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). GSTT1 and GSTM1 genes code for enzymes involved in the metabolism of a wide range of drugs. We hypothesized that this gene variability could be implicated in NVP adverse reactions. METHODS: We analyzed the GSTM1 and GSTT1 null genotypes by multiplex PCR in a population of 181 patients from Mozambique, treated with NVP...
July 8, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28688239/successful-treatment-of-toxic-epidermal-necrolysis-using-plasmapheresis-a-prospective-observational-study
#17
Feng Han, Jingjing Zhang, Qi Guo, Yanjing Feng, Ya Gao, Litao Guo, Yanli Hou, Jingang An, Xiaopeng Wang, Bin Yan, Yan Zheng, Jingchun Song, Manxiang Li, Gang Wang
Toxic epidermal necrolysis (TEN) is a rare, severe, life-threatening skin disease and it requires urgent critical care, including admission to the intensive care unit (ICU). It is characterized by fatal sequelae and high mortality. Currently, insufficient evidence exists to support the use of any systemic adjuvant therapy, such as cyclophosphamide, intravenous immunoglobulin (IVIg), or corticosteroids. However, plasmapheresis has been increasingly valued by clinicians due to its significant efficacy and little adverse side effects...
July 1, 2017: Journal of Critical Care
https://www.readbyqxmd.com/read/28684647/hypersensitivity-to-antipyretics-pathogenesis-diagnosis-and-management
#18
REVIEW
Q U Lee
Antipyretics are commonly prescribed drugs and hypersensitivity occurs at rates of 0.01% to 0.3%. Hypersensitivity can be due to immune mechanisms that include type I to IV hypersensitivity. Type I hypersensitivity results from specific immunoglobulin E production following sensitisation on first exposure. Subsequent exposures elicit degranulation of mast cells, culminating an immediate reaction. Non-type I hypersensitivity is a delayed reaction that involves various effector cells, resulting in maculopapular rash, fixed drug eruptions, drug reaction with eosinophilia and systemic symptoms, and Stevens-Johnson syndrome/toxic epidermal necrolysis...
July 7, 2017: Hong Kong Medical Journal, Xianggang Yi Xue za Zhi
https://www.readbyqxmd.com/read/28682681/de-escalation-strategies-in-human-epidermal-growth-factor-receptor-2-her2-positive-early-breast-cancer-bc-final-analysis-of-the-west-german-study-group-adjuvant-dynamic-marker-adjusted-personalized-therapy-trial-optimizing-risk-assessment-and-therapy-response
#19
Nadia Harbeck, Oleg Gluz, Matthias Christgen, Ronald Ernest Kates, Michael Braun, Sherko Küemmel, Claudia Schumacher, Jochem Potenberg, Stefan Kraemer, Anke Kleine-Tebbe, Doris Augustin, Bahriye Aktas, Helmut Forstbauer, Joke Tio, Raquel von Schumann, Cornelia Liedtke, Eva-Maria Grischke, Johannes Schumacher, Rachel Wuerstlein, Hans Heinrich Kreipe, Ulrike Anneliese Nitz
Purpose Human epidermal growth factor receptor 2 (HER2)-positive/hormone receptor (HR)-positive breast cancer is a distinct subgroup associated with lower chemotherapy sensitivity and slightly better outcome than HER2-positive/HR-negative disease. Little is known about the efficacy of the combination of endocrine therapy (ET) with trastuzumab or with the potent antibody-cytotoxic, anti-HER2 compound trastuzumab emtansine (T-DM1) with or without ET for this subgroup. The West German Study Group trial, ADAPT (Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer) compares pathologic complete response (pCR) rates of T-DM1 versus trastuzumab with ET in early HER2-positive/HR-positive breast cancer...
July 6, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28681589/toxic-epidermal-necrolysis-after-dactinomycin-and-vincristine-combination-chemotherapy-for-nephroblastoma
#20
Yuan Liang, Zhou Yang, Zi-Gang Xu, Lin Ma
In this study, we describe a 2-year-old boy patient with nephroblastoma who has developed toxic epidermal necrolysis (TEN) associated with the combination chemotherapy administration of dactinomycin and vincristine. A skin biopsy confirmed the diagnosis of TEN, and with methylprednisolone pulse therapy, intravenous immunoglobulin (IVIG), and supportive care, the patient improved significantly.
July 2017: Journal of Zhejiang University. Science. B
keyword
keyword
14008
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"